. "Metallomics" . "Sztalmachov\u00E1, Mark\u00E9ta" . . . . . . "KRAS NF-kappa B is involved in the development of zinc resistance and reduced curability in prostate cancer"@en . . . "10.1039/c4mt00065j" . . "25134" . "KRAS NF-kappa B is involved in the development of zinc resistance and reduced curability in prostate cancer"@en . "Gumulec, Jarom\u00EDr" . "[612EC2AF0DAC]" . "RIV/00216224:14110/14:00076568" . . "Holubov\u00E1, Monika" . "1756-5901" . "Adam, Vojt\u011Bch" . . "14110" . "KRAS NF-kappa B is involved in the development of zinc resistance and reduced curability in prostate cancer" . "CITRATE METABOLISM; EPITHELIAL-CELLS; CARCINOMA-CELLS; DNA-DAMAGE; T-ANTIGEN; EXPRESSION; METALLOTHIONEIN; TRANSPORTER; APOPTOSIS; GENES"@en . "9"^^ . "Axmanov\u00E1, Martina" . "O, S, V" . . "Babula, Petr" . . "Masa\u0159\u00EDk, Michal" . . "6"^^ . "Zinc(II) ions are important components of many proteins and are involved in numerous cellular processes such as apoptosis or drug resistance. Prostate cancer has a unique relationship with zinc(II) ions. However, the relationship was examined only in short-term zinc(II) treatments. Therefore, the aim of this study was to create zinc-resistant prostatic cell lines at various stages of the disease (22Rv1 and PC-3) and a normal prostate epithelium (PNT1A) using a long-term zinc exposure. Consequently, the expression profile of the following genes was analyzed: BAX, Bcl-2, Beclin-1, CFLAR, HIF1 alpha, KRAS, mTOR, MT1A, MT2A, NF-kappa B1, p53, survivin, ZIP1, ZnT-1. The resistance was verified using the MTT test; on average a 1.35-fold lower zinc(II) toxicity (higher IC50) was determined in zinc(II)-resistant cells. The associated resistance to cisplatin was also determined; IC50 for cisplatin was 1.52-fold higher."@en . . "6" . . . "KRAS NF-kappa B is involved in the development of zinc resistance and reduced curability in prostate cancer" . . . "14"^^ . "Zinc(II) ions are important components of many proteins and are involved in numerous cellular processes such as apoptosis or drug resistance. Prostate cancer has a unique relationship with zinc(II) ions. However, the relationship was examined only in short-term zinc(II) treatments. Therefore, the aim of this study was to create zinc-resistant prostatic cell lines at various stages of the disease (22Rv1 and PC-3) and a normal prostate epithelium (PNT1A) using a long-term zinc exposure. Consequently, the expression profile of the following genes was analyzed: BAX, Bcl-2, Beclin-1, CFLAR, HIF1 alpha, KRAS, mTOR, MT1A, MT2A, NF-kappa B1, p53, survivin, ZIP1, ZnT-1. The resistance was verified using the MTT test; on average a 1.35-fold lower zinc(II) toxicity (higher IC50) was determined in zinc(II)-resistant cells. The associated resistance to cisplatin was also determined; IC50 for cisplatin was 1.52-fold higher." . . . . "GB - Spojen\u00E9 kr\u00E1lovstv\u00ED Velk\u00E9 Brit\u00E1nie a Severn\u00EDho Irska" . "Raudensk\u00E1, Martina" . . . "000338638000009" . "Kizek, Ren\u00E9" . "7" . . . "RIV/00216224:14110/14:00076568!RIV15-MSM-14110___" . . .